PPD

SEPTEMBER 6, 2023

Mixing of service models — a strategy that drug developers are leveraging now more than ever — can bring life-changing therapies to market faster. LEARN HOW The post How to Optimize Drug Development by Combining FSO and FSP Models appeared first on PPD Inc.

Drug Development 98

Drug Development Clinical Trials Drugs Clinical Research 98

FDA Law Blog: Drug Discovery

MARCH 13, 2023

Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). There have been challenges in gene therapy development.

Therapies 98

Therapies Trials FDA Clinical Trials 98

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

Drug Development 70

Drug Development Metabolic Stability Clinical Trials Drugs 70

DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.

Drug Development 73

Drug Development Clinical Trials Drugs Therapies 73

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Target Review

JULY 18, 2024

Why is detecting cancers via liquid biopsy before they become visible on imaging important for drug development, not just diagnostics? We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.

Drug Development 59

Drug Development Clinical Trials Drugs Vaccine 59

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Hearing aids also have all sorts of deficits.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Drugs 59

Conversations in Drug Development Trends

MARCH 12, 2024

Biomarkers provide a rapid way to inform many clinical oncology study development decisions, including study endpoints. They can inform intervention outcomes, serve as study endpoints, and are advantageous across the spectrum of cancer care. What are they, how do they work, and how can they benefit your oncology study?

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

Drug Target Review

JANUARY 14, 2025

By posing questions such as, ‘Which database should I use to search for data on the effects of longevity drugs in rodents?’ provide more general information. ChatGPT can also aid in deciding which visualisation options are available and what information each will provide, based on the data and your research question.

Drugs 69

Drugs Protein Expression Science Research 69

Drug Patent Watch

JANUARY 9, 2025

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. Staying ahead of trends can help you make more informed decisions.

Compliance 52

Compliance Drug Development Therapies Pharma Companies 52

PPD

JANUARY 5, 2023

In an industry survey led by PPD, Thermo Fisher Scientific’s clinical research business, rare diseases emerged as a top therapeutic area in drug developers’ pipelines, with 39% of global biotech and biopharma leaders pursuing therapies in the broad rare disease space.

Disease 52

Disease Trials Clinical Trials Clinical Research 52

PPD

SEPTEMBER 16, 2024

The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. In a recent panel discussion at DIA Global , our experts explored how these elements are reshaping clinical research and drug discovery.

Clinical Development 98

Clinical Development Clinical Trials Clinical Research Trials 98

FDA Law Blog: Drug Discovery

MAY 19, 2024

aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. More information on the Scientific Workshop can be found here and registration for the live-stream can be found here.

Disease 59

Disease Therapies Drug Development FDA 59

FDA Law Blog: Drug Discovery

MARCH 26, 2024

Sasinowski — On March 21st, FDA announced the approval of the first nonsteroidal therapy for the treatment of Duchenne Muscular Dystrophy (DMD) (FDA press release available here ). Duvyzat (givinostat), a histone deacetylase (HDAC) inhibitor developed by Italfarmaco, S.p.A., By Charles G. Raver & James E. Valentine & Frank J.

FDA Approval 59

FDA Approval Therapies FDA Trials 59

ASPET

JULY 15, 2024

XELOX therapy, which comprises capecitabine and oxaliplatin, is the standard first-line chemotherapeutic regimen for colorectal cancer. This study aimed to develop a translational PK-TD model using rat data to inform dosing strategies and TD implications in humans.

Pharmacokinetics 100

Pharmacokinetics Therapies Drugs Treatment 100

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Premier Consulting Blog

APRIL 18, 2024

Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. As in all nonclinical drug development programs, the goal is to identify potential safety issues in humans. Is fit-for-purpose?

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

With so much information swirling around these days about the coronavirus disease 2019 (COVID-19) pandemic, it would be easy to miss one of the most interesting and significant basic science reports of the past few weeks. Credit: Adapted from Yan R., Science, 2020.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. These challenges have led to strategies such as directly observed therapy (DOT), in which nurses or physicians monitor patients to ensure they take their medicine every day.

Vaccine 96

Vaccine Trials Therapies Clinical Trials 96

Advarra

AUGUST 10, 2023

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating gene therapies.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Antibody drug conjugated with cytotoxic payload.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

NIH Director's Blog: Drug Development

SEPTEMBER 27, 2022

The imprecision can also lead to false leads that won’t pan out further along in the drug development pipeline, at great time and expense to their developers. The researchers are continuing to test their sensor in more cancer models and with more therapies to extend these initial findings.

Drug Development 52

Drug Development Drugs Engineering Therapies 52

Alta Sciences

APRIL 16, 2024

Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs pmjackson Tue, 04/16/2024 - 19:04 The gene therapy landscape continues to accelerate in preclinical and clinical research, with programs constantly in development for targeted, personalized medicines. But how are PCR analysis techniques applied?

Therapies 52

Therapies DNA RNA Laboratories 52

Drug Target Review

DECEMBER 6, 2024

Without this information, the interpretation of the dataset may be speculative or lead to inaccurate conclusions. For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

RNA 52

RNA Drugs Research Science 52

Alta Sciences

MAY 15, 2023

TOP 5 WAYS INTEGRATED DRUG DEVELOPMENT SOLUTIONS SAVE YOU TIME AND MONEY aasimakopoulos Mon, 05/15/2023 - 16:06 Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion , without, for the most part, shorter development timelines.

Drug Development 52

Drug Development Clinical Trials Laboratories Compounding Pharmacies 52

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Therapies 59

Therapies FDA Production Regulations 59

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc.

Therapies 52

Therapies Virus Disease Licensing 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Therapies 59

Therapies Engineering Production FDA 59

Drug Channels

DECEMBER 11, 2020

Sarah describes how historical patient information can be used in current and future clinical trials, often eliminating the need for new trial participants. She also introduces us to Ontada , a new McKesson business that uses technology, real-world data, and research capabilities as a way to accelerate innovation and improve cancer therapies.

Drug Development 52

Drug Development Clinical Trials Drugs Trials 52

Drug Target Review

NOVEMBER 16, 2023

There is a substantial need for new therapies to treat drug-resistant infections without contributing to or perpetuating resistance; therefore, we are committed to developing highly effective treatment solutions that can be used against a broad range of bacterial infections.

Pharmaceuticals 105

Pharmaceuticals Therapies Clinical Trials Trials 105

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

JULY 8, 2021

The update clarifies the indication by emphasizing information about the disease stages studied in the ADUHELM clinical trials. Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies’ statement of June 23, 2021. Please see the full Prescribing Information.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

KIF1A

MARCH 2, 2024

This has created a platform to learn about autism-associated genes, identify risk factors for subgroups, and better inform new interventions. Animal models have given researchers profound insights into disease, assisting in the creation and testing of new therapies that have changed lives across the world.

Laboratories 119

Laboratories Cell Biology Disease Research 119

PPD

AUGUST 28, 2024

For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. For many patients, involvement in oncology clinical trials represents a last hope for an effective therapy.

Trials 69

Trials Clinical Trials Drug Development Therapies 69

Drug Target Review

JANUARY 12, 2024

Most drugs do not work in all people. This one size fits all approach to drug prescribing still pervades in mostly all therapy areas except oncology. Based on the drugs mechanism of action, we can make informed decisions. Also, patients will benefit as there will be more drugs developed.

Doctors 111

Doctors Clinical Trials Treatment Therapies 111

Drug Target Review

JULY 7, 2023

There is a clear need for new and approved, safe, effective and innovative targeted therapies to address the underlying causes of autoantibody diseases. The power of precision therapy Targeted — or precision — therapy, a technique that has been honed for many years in cancer treatment, is now being applied in a wider context.

Disease 98

Disease Immune Response Therapies Treatment 98